FDA Approves New First-Line TNBC Regimen - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

  • By

  • Kathryn Wighton

  • June 26, 2026

  • 3 min

Share

Clinical Report: FDA Approves New First-Line TNBC Regimen

Overview

The FDA has approved pembrolizumab and its combination with sacituzumab govitecan-hziy for first-line treatment of unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) in patients with PD-L1 expression. This approval is based on the KEYNOTE-D19/ASCENT-04 trial.

Background

Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen, progesterone, and HER2 receptors, leading to limited treatment options. The combination of immunotherapy and antibody-drug conjugates is a new approach in the management of mTNBC.

Data Highlights

RegimenMedian PFS (months)Objective Response Rate (%)Complete Response Rate (%)
Pembrolizumab + Sacituzumab govitecan-hziy11.26112
Pembrolizumab + Chemotherapy7.8558

Key Findings

  • The FDA approved pembrolizumab and its combination with sacituzumab govitecan-hziy for first-line treatment of PD-L1-positive mTNBC.
  • The KEYNOTE-D19/ASCENT-04 trial enrolled 443 patients and demonstrated a 35% reduction in the risk of disease progression or death with the new regimen.
  • Median progression-free survival was significantly longer with pembrolizumab plus sacituzumab govitecan-hziy (11.2 months) compared to chemotherapy (7.8 months).
  • The objective response rate was 61% for the combination therapy versus 55% for chemotherapy.
  • Common adverse reactions included decreased neutrophil count, diarrhea, and fatigue, with serious adverse reactions occurring in 38% of patients.

Clinical Implications

The approval of pembrolizumab in combination with sacituzumab govitecan-hziy provides a new first-line treatment option for patients with PD-L1-positive mTNBC.

Conclusion

This combination therapy has been approved for the treatment of patients with advanced triple-negative breast cancer.

Related Resources & Content

  1. Merck, FDA, 2026 -- FDA Approves New First-Line TNBC Regimen
  2. The ASCO Post — FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC
  3. The ASCO Post — NCCN Clinical Practice Guidelines in Oncology: 2024 Updates
  4. The ASCO Post — FDA Oncology Drug Approvals Granted Between June 2017 and May 16, 2018
  5. dana-farber — Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
  6. FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC
  7. NCCN Clinical Practice Guidelines in Oncology: 2024 Updates
  8. FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer | FDA
  9. Trodelvy® Added as Preferred Regimen Within First-Line Metastatic Triple-Negative Breast Cancer in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
  10. Sacituzumab Govitecan With Pembrolizumab Extends Progression-Free Survival 2 for Some People With Metastatic Triple-Negative Breast Cancer - ASCO

Original Source(s)

FDA Approves New First-Line TNBC Regimen

  • by Kathryn Wighton

  • June 26, 2026

Related Content

Self-Sampling Shows Test Agreement

The study authors frame the device as a potential way to simplify screening, while emphasizing that larger validation studies are still needed.

FDA approves serial liquid biopsy testing

In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.

Is Accelerated Aging Tied to Early-Onset Carcinogenesis?

Researchers found larger biological age gaps in more recent birth cohorts and observed associations with higher risk of several cancers diagnosed before age 55.